AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
1.380
-0.090 (-6.12%)
Dec 5, 2025, 4:00 PM EST - Market closed
AIM ImmunoTech Employees
As of December 31, 2024, AIM ImmunoTech had 23 total employees, including 21 full-time and 2 part-time employees. The number of employees decreased by 5 or -17.86% compared to the previous year.
Employees
23
Change (1Y)
-5
Growth (1Y)
-17.86%
Revenue / Employee
$4,870
Profits / Employee
-$684,783
Market Cap
3.94M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AIM News
- 4 days ago - AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series - GlobeNewsWire
- 17 days ago - AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program - GlobeNewsWire
- 23 days ago - Aimia Inc. (AIM:CA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer - GlobeNewsWire
- 4 weeks ago - AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - GlobeNewsWire
- 6 weeks ago - AIM ImmunoTech to Attend the 2025 Maxim Growth Summit - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors - GlobeNewsWire
- 3 months ago - AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland - GlobeNewsWire